NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NUV-868’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NUV-868 is under development for the treatment of acute myeloid leukemia and advanced solid tumors including ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, metastatic castration resistant prostate cancer (mCRPC) and triple negative breast cancer (TNBC). It is administered through oral route. The drug candidate targets bromodomain-containing protein 4 (BRD4).
Nuvation Bio overview
Nuvation Bio is a biotechnology company developing proprietary therapies focused on oncology. The companies proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company is headquartered in New York City, New York, the US.
For a complete picture of NUV-868’s drug-specific PTSR and LoA scores, buy the report here.